• PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers
• Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial
• Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks
• Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.